Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease

Neurobiology of Disease

Volumn 17, Issue 3, 2004, Pages 455-461

  Guidetti, Paolo ^a   Luthi Carter, Ruth E ^b   Augood, Sarah J ^b   Schwarcz, Robert ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

3 Hydroxykynurenine; Excitotoxicity; Excitotoxins; Free radicals; Kynurenic acid; Kynurenines; Neurodegeneration; Neuroprotection

Indexed keywords

3 HYDROXYKYNURENINE; KYNURENIC ACID; QUINOLINIC ACID; TRYPTOPHAN;

ARTICLE; BRAIN LEVEL; CEREBELLUM; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; NEOCORTEX; NERVE CELL NECROSIS; PATHOGENESIS; PRIORITY JOURNAL; STRIATE CORTEX;

AGED; ANALYSIS OF VARIANCE; CEREBELLUM; CEREBRAL CORTEX; FRONTAL LOBE; HUMANS; HUNTINGTON DISEASE; KYNURENIC ACID; MIDDLE AGED; NEOSTRIATUM; QUINOLINIC ACID;

EID: 9644270316     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2004.07.006     Document Type: Article

References (55)

1. E. Aizenman Modulation of N-methyl-d-aspartate receptors by hydroxyl radicals in rat cortical neurons in vitro Neurosci. Lett. 189 1995 57 59
2. M. Aschner, U. Sonnewald, and K.H. Tan Astrocyte modulation of neurotoxic injury Brain Pathol. 12 2002 475 481
3. G. Bates Huntingtin aggregation and toxicity in Huntington's disease Lancet 361 2003 1642 1644
4. M.F. Beal, W.R. Matson, K.J. Swartz, P.H. Gamache, and E.D. Bird Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid J. Neurochem. 55 1990 1327 1339
5. M.F. Beal, W.R. Matson, E. Storey, P. Milkury, E.A. Ryan, T. Ogawa, and E.D. Bird Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex J. Neurol. Sci. 108 1992 80 87
6. D.A. Butterfield, B.J. Howard, and M.A. LaFontaine Brain oxidative stress in animal models of accelerated aging and the age-related neurodegenerative disorders, Alzheimer's disease and Huntington's disease Curr. Med. Chem. 8 2001 815 828
7. C. Cepeda, M.A. Ariano, C.R. Calvert, J. Flores-Hernandez, S.H. Chandler, B.R. Leavitt, M.R. Hayden, and M.S. Levine NMDA receptor function in mouse models of Huntington disease J. Neurosci. Res. 66 2001 525 539
8. C. Cepeda, R.S. Hurst, C.R. Calvert, E. Hernandez-Echeagaray, O.K. Nguyen, E. Jocoy, L.J. Christian, M.A. Ariano, and M.S. Levine Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease J. Neurosci. 23 2003 961 969
9. A. Chiarugi, E. Meli, and F. Moroni Similarities and differences in the neuronal death processes activated by 3OH-kynurenine and quinolinic acid J. Neurochem. 77 2001 1310 1318
10. C.B. Dunlap Pathologic changes in Huntington's chorea with special reference to the corpus striatum Arch. Neurol. Psychiatry 18 1927 867 943
11. M.B. Feany, and A.R. La Spada Polyglutamines stop traffic: axonal transport as a common target in neurodegenerative diseases Neuron 40 2003 41 52
12. A.C. Foster, A. Vezzani, E.D. French, and R. Schwarcz Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid Neurosci. Lett. 48 1984 273 278
13. A.C. Foster, W.O. Whetsell Jr., E.D. Bird, and R. Schwarcz Quinolinic acid phosphoribosyltransferase in human and rat brain: activity in Huntington's disease and in quinolinate-lesioned rat striatum Brain Res. 336 1985 207 214
14. S. Gines, E. Ivanova, I.S. Seong, C.A. Saura, and M.E. MacDonald Enhanced Akt signaling is an early pro-survival response that reflects NMDA receptor activation in Huntington's disease knock-in striatal cells J. Biol. Chem. 278 2003 50514 50522
15. P. Guidetti, and R. Schwarcz 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum Eur. J. Neurosci. 11 1999 3857 3863
16. P. Guidetti, P.H. Reddy, D.A. Tagle, and R. Schwarcz Early kynurenergic impairment in Huntington's disease and in a transgenic animal model Neurosci. Lett. 283 2000 233 235
17. P. Guidetti, R.E. Luthi-Carter, S.J. Augood, and R. Schwarcz Quinolinic acid levels are increased in early grade Huntington's disease Abstr.-Soc. Neurosci. 29 2003 208.7
18. O. Hansson, E. Guatteo, N.B. Mercuri, G. Bernardi, X.J. Li, R.F. Castilho, and P. Brundin Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the Huntington gene Eur. J. Neurosci. 14 2001 1492 1504
19. M.P. Heyes, K.J. Swartz, S.P. Markey, and M.F. Beal Regional brain and cerebrospinal fluid quinolinic acid concentrations in Huntington's disease Neurosci. Lett. 122 1991 265 269
20. M.P. Heyes, K. Saito, J.S. Crowley, L.E. Davis, M.A. Demitrack, M. Der, L.A. Dilling, J. Elia, M.J. Kruesi, and A. Lackman Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease Brain 115 1992 1249 1273
21. D. Jauch, E.M. Urbanska, P. Guidetti, E.D. Bird, J.-P.G. Vonsattel, W.O. Whetsell, and R. Schwarcz Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases J. Neurol. Sci. 130 1995 37 47
22. S.J. Kerr, P.J. Armati, G.J. Guillemin, and B.J. Brew Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex AIDS 12 1998 355 363
23. N.G. Kim, H. Lee, E. Son, O.Y. Kwon, J.Y. Park, J.H. Park, G.J. Cho, W.S. Choi, and K. Suk Hypoxic induction of caspase-11/caspase-1/interleukin-1beta in brain microglia Brain Res. Mol. Brain Res. 114 2003 107 114
24. C. Kiss, G. Ceresoli-Borroni, P. Guidetti, C.L. Zielke, H.R. Zielke, and R. Schwarcz Kynurenate production by cultured human astrocytes J. Neural Transm. 110 2003 1 14
25. G.A. Laforet, E. Sapp, K. Chase, C. McIntyre, F.M. Boyce, M. Campbell, B.A. Cadigan, L. Warzecki, D.A. Tagle, P.H. Reddy, C. Cepeda, C.R. Calvert, E.S. Jokel, G.J. Klapstein, M.A. Ariano, M.S. Levine, M. DeFiglia, and N. Aronin Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease J. Neurosci. 23 2001 9112 9123
26. M.S. Levine, G.J. Klapstein, A. Koppel, E. Gruen, C. Cepeda, M.E. Vargas, E.S. Jokel, E.M. Carpenter, H. Zanjani, R.S. Hurst, A. Efstratiadis, S. Zeitlin, and M.F. Chesselet Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knock-in mouse models of Huntington's disease J. Neurosci. Res. 58 1999 515 532
27. A. Lewen, P. Matz, and P.H. Chan Free radical pathways in CNS injury J. Neurotrauma 17 2000 871 890
28. H. Li, T. Wyman, Z.X. Yu, S.H. Li, and X.J. Li Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release Hum. Mol. Genet. 12 2003 2021 2030
29. L. Li, M. Fan, C.D. Icton, N. Chen, B.R. Leavitt, M.R. Hayden, T.H. Murphy, and L.A. Raymond Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease Neurobiol. Aging 24 2003 1113 1121
30. J.C. Lievens, B. Woodman, A. Mahal, O. Spasic Boscovic, D. Samuel, L. Kerkerian-LeGoff, and G.P. Bates Impaired glutamate uptake in the R6 Huntington's disease transgenic mice Neurobiol. Dis. 8 2001 807 821
31. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with Folin phenol reagent J. Biol. Chem. 193 1951 265 275
32. R. Luthi-Carter, and J.H.J. Cha Mechanisms of transcriptional dysregulation in Huntington's disease Clin. Neurosci. Res. 3 2003 165 177
33. R. Luthi-Carter, B.L. Apostol, A.W. Dunah, M.M. DeJohn, L.A. Farrell, G.P. Bates, A.B. Young, D.G. Standert, L.M. Thompson, and J.H. Cha Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation Neurobiol. Dis. 14 2003 624 636
34. M.E. MacDonald, S. Gines, J.F. Gusella, and V.C. Wheeler Huntington's disease Neuromol. Med. 4 2003 7 20
35. G.A. MacGibbon, L.C. Hamilton, S.F. Crocker, W.J. Costain, K.M. Murphy, H.A. Robertson, and E.M. Denovan-Wright Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice J. Neurosci. Res. 67 2002 372 378
36. D.B. Naritsin, R.L. Boni, and S.P. Markey Pentafluorobenzylation method for quantification of acidic tryptophan metabolites using electron capture negative ion mass spectrometry Anal. Chem. 67 1995 863 870
37. S. Okuda, N. Nishiyama, H. Saito, and H. Katsuki Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine Proc. Natl. Acad. Sci. U. S. A. 93 1996 12553 12558
38. A.V. Panov, C.A. Gutekunst, B.R. Leavitt, M.R. Hayden, J.R. Burke, W.J. Strittmatter, and J.T. Greenamyre Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines Nat. Neurosci. 5 2002 731 736
39. S.J. Pearson, and G.P. Reynolds Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease Neurosci. Lett. 144 1992 199 201
40. G.P. Reynolds, S.J. Pearson, J. Halket, and M. Sandler Brain quinolinic acid in Huntington's disease J. Neurochem. 50 1988 1959 1960
41. C. Rios, and A. Santamaria Quinolinic acid is a potent lipid peroxidant in rat brain homogenates Neurochem. Res. 16 1991 1139 1143
42. H.D. Rosas, W.J. Koroshetz, Y.I. Chen, C. Skeuse, M. Vangel, M.E. Cudkowicz, K. Caplan, K. Marek, L.J. Seidman, N. Makris, B.G. Jenkins, and J.M. Goldstein Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis Neurology 60 2003 1615 1620
43. E. Sapp, K.B. Kegel, N. Aronin, T. Hashikawa, Y. Uchiyama, K. Tohyama, P.G. Bhide, J.P. Vonsattel, and M. DiFiglia Early and progressive accumulation of reactive microglia in the Huntington disease brain J. Neuropathol. Exp. Neurol. 60 2001 161 172
44. R. Schwarcz, and R.L. Albin Huntington's disease D. Lodge W. Danysz C.G. Parsons Ionotropic Glutamate Receptors as Therapeutic Targets 2002 FP Graham Publishing Co. Tennessee 587 610
45. R. Schwarcz, and R. Pellicciari Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities J. Pharmacol. Exp. Ther. 303 2002 1 10
46. R. Schwarcz, W.O. Whetsell Jr., and R.M. Mangano Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain Science 219 1983 316 318
47. R. Schwarcz, E. Okuno, R.J. White, E.D. Bird, and W.O. Whetsell Jr. 3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims Proc. Natl. Acad. Sci. U. S. A. 85 1988 4079 4081
48. R. Schwarcz, C.A. Tamminga, R. Kurlan, and I. Shoulson Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia Ann. Neurol. 24 1988 580 582
49. C. Speciale, and R. Schwarcz Uptake of kynurenine into rat brain slices J. Neurochem. 54 1990 156 163
50. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 1993 971 983
51. S. Vazquez, B. Garner, M.M. Sheil, and R.J. Truscott Characterization of the major autoxidation products of 3-hydroxykynurenine under physiological conditions Free Radical Res. 32 2000 11 23
52. J.P. Vonsattel, R.H. Myers, T.J. Stevens, R.J. Ferrante, E.D. Bird, and E.P. Richardson Jr. Neuropathological classification of Huntington's disease J. Neuropathol. Exp. Neurol. 44 1985 559 577
53. W.O. Whetsell Jr., and R. Schwarcz Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat corticostriatal system Neurosci. Lett. 97 1989 271 275
54. H.Q. Wu, P. Guidetti, J.H. Goodman, M. Varasi, G. Ceresoli-Borroni, C. Speciale, H.E. Scharfman, and R. Schwarcz Kynurenergic manipulations influence excitatory synaptic function and excitotoxic vulnerability in the rat hippocampus in vivo Neuroscience 97 2000 243 251
55. M.M. Zeron, O. Hansson, N. Chen, C.L. Wellington, B.R. Leavitt, P. Brundin, M.R. Hayden, and L.A. Raymond Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease Neuron 33 2002 849 860